vTv Therapeutics (VTVT) Cash from Operations (2014 - 2026)

vTv Therapeutics has disclosed Cash from Operations across 13 years of filings, most recently posting -$11.4 million for Q2 2026.

• In Q2 2026, Cash from Operations fell 124.59% year-over-year to -$11.4 million; the TTM figure through Jun 2026 stood at -$16.8 million (up 23.9% YoY), while the FY2025 annual figure was -$25.3 million, changed 0.21% from the prior year.
• Cash from Operations came in at -$11.4 million for Q2 2026 at vTv Therapeutics, down from $9.2 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $9.2 million in Q1 2026 to a low of -$11.4 million in Q2 2026.
• Average Cash from Operations over 5 years is -$4.9 million, with a median of -$5.5 million recorded in 2025.
• Year-over-year, Cash from Operations tumbled 973.51% in 2023 and soared 260.96% in 2026.
• Over 5 years, Cash from Operations stood at -$6.9 million in 2022, then jumped by 57.65% to -$2.9 million in 2023, then tumbled by 65.58% to -$4.8 million in 2024, then sank by 91.73% to -$9.3 million in 2025, then dropped by 23.69% to -$11.4 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$11.4 million in Q2 2026, $9.2 million in Q1 2026, and -$9.3 million in Q4 2025.